8 research outputs found
84 Aztreonam 75 mg powder and solvent for nebuliser solution (AZLI) in cystic fibrosis (CF) patients with chronic Burkholderia species (Burk) infection: baseline demographics and microbiology from a randomized, placebo-controlled trial
No full text58 No antibiotic cross-resistance after 1 year of continuous aztreonam for inhalation solution (AZLI) in cystic fibrosis (CF) patients (pts) with chronic Burkholderia (BURK) infection
No full textOpen label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.
No full text
Hepatic regeneration and metabolism after partial hepatectomy in normal rats: effects of insulin therapy
No full textRandomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia
Get PDFThis study was funded by Gilead Sciences, Inc. M. B., W. G. and M. J. H.
are employees of Gilead Sciences. All other authors or their institutions
have received compensation for study participation from Gilead Sciences
International Ltd
